Phase II Clinical Trial of Percutaneous Ventricular Restoration Using Heartech® Device Preventing Heart Failure Post Myocardial Infarction (The Partical Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-02

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, multi-center, single-group, target-value clinical study. The primary safety end points are major adverse cardiovascular events (MACCE) 30 days after device implantation.

The primary efficacy end point is the end of left ventricular systolic volume index (LVESVI) reduction at 6 month.

The secondary observational end points includes immediate success rate of the procedure, all-cause mortality, cardiac death, rehospitalization rates and MACCE occurrence rate within 12 month. Besides, left ventricular end systolic volume index (LVESVI) change at 30 days,12 months, left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume index (LVEDVI), 6 minutes walk test, heart function evaluation (NYHA classification) and quality of life (EQ-5D) at 30 days, 6 months, 12 months will also be evaluated.

After statistical hypothesis and sample size estimation, the sample size of this clinical trial was 117 cases. All subjects were followed up 30 days, 6 months and 12 months after implantation of the Heartech® left ventricular partitioning device. All relevant clinical data were managed by professional data management center, and all relevant clinical data were statistically analyzed by third-party statistical center.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure

NCT00751972

Chronic Heart Failure

COMPLETED NA

Assessment of Safety and Accuracy of the Microtech System in Patients Undergoing Left Ventricular Assist Device Implantation

NCT06682910

Heart Failure

RECRUITING NA

A Clinical Trial to Evaluate the HeartWare MVAD® System (MVAdvantage)

NCT01831544

Heart Failure

TERMINATED NA

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

NCT01240902

Severe Aortic Stenosis

COMPLETED NA

Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure

NCT00834145

Right Heart Failure Cor Pulmonale

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MACCE includes all-cause death, myocardial infarction, stroke and any elective or emergency cardiac or thoracic aortic surgery or catheter-based interventional therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Efficacy, Safty, Device

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PVR implantation group

Patients enrolled receive PVR intervention

Group Type EXPERIMENTAL

percutaneous ventricular restoration using heartech® device

Intervention Type DEVICE

Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

percutaneous ventricular restoration using heartech® device

Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI\<40;
* left ventricular ejection fraction ≤45% and ≥20%;
* patients with left ventricular end-systolic volume index (ESVI) ≥50mL/m2;
* transthoracic ultrasound showed contradictory motion of the left ventricle after myocardial infarction;
* 60 days prior to anterior wall myocardial infarction with ischemic heart failure (NYHA grade II to "not hospitalized" grade IV);
* the left ventricle must have the appropriate anatomic structure (size and shape) which is confirmed by cardiac CT and left ventricular angiography to implant the appropriate Heartech® device;
* agree to receive reasonable treatment according to current ACC/AHA and Chinese guidelines for heart failure diagnosis and treatment;
* the subjects or their legal representatives are informed of the nature of this study and agree to participate in all the terms of this study, sign the informed consent approved by the ethics committee, agree to accept the postoperative treatment plan and follow-up requirements, and can complete the examination of follow-up.

Exclusion Criteria

* patients whose left ventricular anatomy is not suitable for Heartech® occlusal device implantation;
* the abnormal ventricular wall movement not contains the anterior wall of the left ventricle, the apex of the left ventricle and the ventricular septum;
* patients with thrombosis in the left ventricle;
* mitral stenosis or regurgitation (tricuspid, aortic or mitral) \> 2+ (moderate);
* recent (within 6 month) cerebrovascular accident (CVA) or transient ischemic attack (TIA);
* end-stage renal disease requiring long-term dialysis, episodic sepsis or active phase endocarditis;
* life expectancy at admission \< 1 year;
* known allergy to aspirin, heparin, warfarin, Nitinol (alloys of titanium and nickel) or contraindications, or sensitivity to contrast agents;
* cardiogenic shock occurred within 72 hours before procedure;
* pregnancy or planned pregnancy during the study period;
* participated in clinical trials of other drugs or medical devices during the same period;
* the researcher judged that the patient had poor compliance and could not complete the study as required;
* other conditions considered unsuitable for participation in this clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No